Baseline demographic and clinical characteristics of the Chinese subgroup and overall study population in CHEST-1
| Chinese subgroup | Overall study population | |||||
|---|---|---|---|---|---|---|
| Characteristic | Placebo (n=11) | Riociguat 2.5 mg-maximum group (n=21) | Total (n=32) | Placebo (n=88) | Riociguat 2.5 mg-maximum group (n=173) | Total (n=261) |
| Female, n (%) | 8 (73) | 14 (67) | 22 (69) | 54 (61) | 118 (68) | 172 (66) |
| Age, mean±SD (years) | 52±13 | 47±10 | 49±11 | 59±13 | 59±14 | 59±14 |
| WHO FC I/II/III/IV, % | 0/55/45/0 | 10/52/38/0 | 6/53/41/0 | 0/28/68/2* | 2/32/62/5 | 1/31/64/4* |
| CTEPH, n (%) | ||||||
| Inoperable | 10 (91) | 19 (91) | 29 (91) | 68 (77) | 121 (70) | 189 (72) |
| Postoperative | 1 (9) | 2 (10) | 3 (9) | 20 (23) | 52 (30) | 72 (28) |
| 6MWD, mean±SD (m) | 364±85 | 375±57 | 371±67 | 356±75 | 342±82 | 347±80 |
*Data missing for one patient.
6MWD, 6 min walking distance; CTEPH, chronic thromboembolic pulmonary hypertension; WHO FC, WHO functional class (ranges from I to IV, with higher numbers indicating greater functional limitations).